Loading issue research
Support therapeutic somatic genome medicine with safety registries, access, privacy, manufacturing capacity, and a hard clinical boundary around reproductive germline editing.
Verification Status
AI-researched, unverifiedLast Reviewed
Jul 6, 2026
Cited Sources
6
The specific delta between this position and the current mainstream approaches of both major parties.
Democrats are often stronger on health access, NIH funding, anti-discrimination, and patient protection. Republicans are often stronger on skepticism toward federal overreach, faster review pathways, and concern that regulation can slow cures. Both positions can be useful. Either can fail if isolated: access rhetoric without regulatory capacity does not produce safe therapies, and speed rhetoric without registries, privacy, and payment design does not produce trustworthy medicine.
The Innovation Party's delta is a two-lane rule. Move therapeutic somatic genome medicine forward with public standards and access. Keep clinical reproductive germline editing outside approved care until the country can honestly answer the safety and consent questions. The position is pro-cure and pro-boundary.
Turn frustration into useful pressure.
If this position misses evidence or a lived consequence, challenge it. If it holds up, help test it locally and connect it to the issues around it.